ARTICLE | Clinical News

Genasense oblimersen sodium injection: Additional Phase III data

November 23, 2009 8:00 AM UTC

Additional data from the double-blind, international Phase III AGENDA trial in 314 patients showed that Genasense plus dacarbazine (DTIC) led to a median PFS of 2.8 months vs. 2.7 months for placebo p...